MCC Meds Flashcards
Bevacizumab MOA
Monoclonal antibody which binds to, and neutralizes, vascular endothelial growth factor (VEGF), preventing its association with endothelial receptors
Bevacizumab AEs
Acute: Hypertension, infusion reactions. Delayed: Arterial thromboembolic events, gastrointestinal perforations, wound healing complications, proteinuria
Cetuximab MOA
Binds to EGFR (HER1, c-ErbB-1) competitively inhibits binding of EGF and other ligands.
Binding to EGFR blocks phosphorylation and activation of receptor-associated kinases -> inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production.
EGFR signal transduction -> RAS wild-type activation; cells with RAS mutations appear to be unaffected by EGFR inhibition.
Cetuximab AEs
Acute: Infusion reactions. Delayed: Acneiform rash, hypomagnesemia, fatigue, diarrhea.
Erlotinib MOA
Reversibly inhibits overall HER1/EGFR tyrosine kinase activity. Intracellular phosphorylation inhibited, preventing downstream signaling, -> cell death. Higher binding affinity for EGFR exon 19 deletion or exon 21 L858R mutations than for the wild type receptor.
Erlotinib AEs
What cancer drug is associated w/ cardiotoxicity?
Traztuzumab
- binds HER2 (an epidermal growth factor w/ extracellular domain) and inhibits cell proliferation from overexpressed HER2 protein
What cancer meds are associated w/ acneiform rash?
Cetuximab -EGFR mAbs
and
Erlotinib - EGFR TKI
What is Imatinib used for?
CML
Inhibits BCR-ABL tyrosine kinase
What AE is Nivolumab associated with?
Immune-related adverse events (IRAEs)
-diarrhea, endocrinopathies, hepatitis
Nivolumab MOA
Selectively inhibits PD-1 or PD-L1
Doxorubicin MOA
DNA intercalator that generates DNA damage by forming ROS
also inhibits topoisomerases
Doxorubicin AE
Total-dose cardiovascular toxicity
